Site Editor

Leo I. Gordon, MD, FACP


ESMO 2022: Novel Antibody-Drug Conjugate Under Study in B-Cell Lymphoma

By: Justine Landin, PhD
Posted: Friday, September 23, 2022

The anti-CD20–monomethyl auristatin E (MMAE) antibody-drug conjugate TRS005 appears to be well tolerated and may improve clinical outcomes for some patients with relapsed or refractory B-cell non-Hodgkin lymphoma, according to the preliminary results from a phase I study conducted at 11 centers in China. These findings were presented by Yuan-Kai Shi, MD, of the Chinese Academy of Medical Sciences, Beijing, during the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract 618O).

“TRS005...targets CD20-positive tumor cells to deliver MMAE, a highly toxic antimitotic agent, into the cells via receptor-mediated endocytosis,” stated the study investigators.

Patients with relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma (n = 40) received intravenous TRS005 on the first day of each 21-day cycle for six cycles. The dose-escalation phase included seven cohorts ranging from to 2.3 mg/kg. Dose-limiting toxicity was observed in the 2.1-mg/kg cohort because of liver damage. Treatment-related adverse events were observed in 78% of patients, 34.1% of which were grade 3 or higher, and neutropenia was the most common (10.1%).

At the data cutoff date, the overall response rate was 37.1%, and the disease control rate was 60%. The overall response and disease control rates across dose cohorts were at least 42.9% and at least 57.1%, respectively, apart from the 1.0-mg/kg dose (16.7% and 16.7%). The highest dose (1.8 mg/kg) yielded an overall response rate of 50% and a disease control rate of 100% in four patients. Across histology subtypes, the overall response and disease control rates in patients with follicular lymphoma were 21.4% and 42.9%, respectively, and in diffuse large B-cell lymphoma, 46.7% and 66.7%, respectively. For patients with mantle cell lymphoma and marginal zone lymphoma, the overall response and disease control rates were both 100%.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.